




Nomogram to predict resumption of regular menstruation after sleeve gastrectomy in patients with polycystic ovary syndrome

Xin Huang, Yian Zhao, Shaozhuang Liu

Department of Bariatric and Metabolic Surgery, Qilu Hospital of Shandong University, China

State Key Laboratory of Diabetes and Obesity Surgery, Shandong University, China



Polycystic Ovary Syndrome (PCOS)

- 10%-13% prevalence
- Most common endocrinopathy in reproductive-aged women
- The pathology of PCOS
 - ① insulin resistance
 - ② hyperinsulinemia
- Diagnosis (Rotterdam criteria)
 - ① oligo-/amenorrhea
 - ② clinical/biochemical hyperandrogenism
 - ③ polycystic ovary morphology (PCOM)

Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome[†]

Consensus Recommendations

- Bariatric/ metabolic surgery could be considered to improve weight loss, hypertension, diabetes (prevention and treatment), hirsutism, irregular menstrual cycles, ovulation, and pregnancy rates in women with PCOS.
- PCOS is a metabolic condition and could be considered an indication at a lower BMI threshold for bariatric/ metabolic surgery similarly to other metabolic conditions including diabetes.



Teede HJ, et al. Hum Reprod. 2023 Sep 5.



Multi-center, prospective cohort: Sleeve Gastrectomy for Obese PCOS (SGOP)

Clinical trial registry: [Chinese Clinical Trial Registry \(No. ChiCTR1900026845\)](#)

[Clinicaltrials.gov \(2020SDUCRCC024\)](#)




Zhao Y, et al. Front Endocrinol (Lausanne). 2024 Mar 11.

Question:

Is it possible to identify the population preoperatively that can/can't benefit from SG in terms of menstrual regularity?

Objective:

To develop and validate a nomogram to predict resumption of regular menstruation after SG in patients with oligo-/anovulatory PCOS.




Univariate and Multivariate Logistic Regression Analyses

Variables	Univariate			Multivariate		
	OR	95%CI	P value	OR	95%CI	P value
Age, ≥ 33.5 vs < 33.5 , years	2.58	0.56-11.88	0.22			
BMI, ≥ 43.08 vs < 43.08 , kg/m ²	1.40	0.58-3.37	0.45			
WHR, ≥ 0.89 vs < 0.89	3.20	1.29-7.96	0.01	8.23	2.31-29.36	< 0.01
Body lean ratio, ≥ 50.74 vs < 50.74 , %	1.70	0.72-4.05	0.23			
Body fat ratio, ≥ 42.19 vs < 42.19 , %	2.00	0.87-4.59	0.10			
Visceral fat ratio, ≥ 0.82 vs < 0.82 , %	1.88	0.82-4.30	0.14			
Nas, ≥ 4.5 vs < 4.5	0.56	0.24-1.31	0.18			
PCOM, Yes vs No	0.32	0.07-1.45	0.14			
Testosterone, ≥ 1.27 vs < 1.27, nmol/L	3.76	1.60-8.83	< 0.01	4.20	1.41-12.54	0.01
AMH, ≥ 4.01 vs < 4.01 , ng/ml	1.43	0.63-3.27	0.39			
FSH, ≥ 5.73 vs < 5.73 , mIU/ml	0.70	0.31-1.61	0.40			
LH, ≥ 10.27 vs < 10.27 , mIU/ml	2.82	0.79-10.07	0.11			
LH/FSH, ≥ 1.78 vs < 1.78	1.69	0.66-4.31	0.28			
PRL, ≥ 353.61 vs < 353.61, μIU/ml	0.31	0.13-0.74	0.01	0.29	0.10-0.87	0.03

Univariate and Multivariate Logistic Regression Analyses (Continued)

Variables	Univariate			Multivariate		
	OR	95%CI	P value	OR	95%CI	P value
FPG, ≥ 5.78 vs < 5.78 , <u>mmol/L</u>	1.35	0.56-3.25	0.51			
Fasting insulin, ≥ 23.33 vs < 23.33 , <u>mIU/L</u>	0.52	0.22-1.26	0.15			
HbA1c, ≥ 5.95 vs < 5.95 , %	0.52	0.23-1.20	0.13			
<u>HOMA-IR</u>, ≥ 5.95 vs < 5.95	0.43	0.17-1.10	0.08	0.09	0.02-0.37	< 0.01
AUC glucose, ≥ 18.43 vs < 18.43	1.47	0.64-3.38	0.36			
<u>AUC insulin</u>, ≥ 239 vs < 239	3.26	0.92-11.61	0.07	6.54	1.35-31.72	0.02
<u>HDL-C</u> , ≥ 1.10 vs < 1.10 , <u>mmol/L</u>	0.53	0.23-1.23	0.14			
<u>Non-HDL-C</u>, ≥ 3.34 vs < 3.34, <u>mmol/L</u>	3.13	1.35-7.30	0.01	4.64	1.56-13.77	0.01
NEFA, ≥ 48.5 vs < 48.5 , <u>umol/dL</u>	3.06	1.05-8.92	0.04			



Accuracy of the Prediction Score of the Nomogram

Variables [↵]	Value (95%CI) [↵]		
	Training Cohort [↵]	Internal validation cohort [↵]	External validation cohort [↵]
Area under ROC curve, [↵]	0.85 (0.77-0.94) [↵]	0.86 (0.73-0.99) [↵]	0.83 (0.70-0.96) [↵]
Sensitivity, % [↵]	92.5 (87.4-97.5) [↵]	93.3 (84.4-100) [↵]	73.7 (53.9-93.5) [↵]
Specificity, % [↵]	69.0 (52.1-85.8) [↵]	66.7 (35.9-97.5) [↵]	85.7 (70.7-100) [↵]
Positive predictive value, % [↵]	91.6 (86.3-96.8) [↵]	90.3 (79.9-101) [↵]	82.4 (64.2-101) [↵]
Negative predictive value, % [↵]	71.4 (54.7-88.2) [↵]	75.0 (45.0-105) [↵]	78.3 (61.4-95.1) [↵]
Positive likelihood ratio [↵]	2.98 (1.73-5.14) [↵]	2.80 (1.11-7.09) [↵]	5.16 (1.75-15.2) [↵]
Negative likelihood ratio [↵]	0.11 (0.05-0.22) [↵]	0.10 (0.02-0.41) [↵]	0.31 (0.14-0.67) [↵]

Fingdings & Highlights

- SG achieved significant resumption of regular menstruation in patients with oligo-/anovulatory PCOS
- A nomogram combining six preoperative factors was developed and validated to predict the resumption.
- Independent positive predictors included AUCinsulin, Non-HDL-C, WHR, and total testosterone
- HOMA-IR and PRL were negative predictors

The impact of type 2 diabetes on polycystic ovary syndrome in patients undergoing sleeve gastrectomy

Xin Huang, Yian Zhao, Shaozhuang Liu Qilu Hospital of Shandong University, China



Thanks for your attention!

Have a good day!

Xin Huang, Yian Zhao, Shaozhuang Liu

Department of Bariatric and Metabolic Surgery, Qilu Hospital of Shandong University, China

State Key Laboratory of Diabetes and Obesity Surgery, Shandong University, China